Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Telehealth company Hims & Hers is running its first Super Bowl ... the negative impact of obesity on individuals and society at large. The ad also criticizes the U.S. healthcare system for people ...